JP2017519768A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519768A5
JP2017519768A5 JP2016573926A JP2016573926A JP2017519768A5 JP 2017519768 A5 JP2017519768 A5 JP 2017519768A5 JP 2016573926 A JP2016573926 A JP 2016573926A JP 2016573926 A JP2016573926 A JP 2016573926A JP 2017519768 A5 JP2017519768 A5 JP 2017519768A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
binding fragment
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016573926A
Other languages
English (en)
Japanese (ja)
Other versions
JP6845016B2 (ja
JP2017519768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/036576 external-priority patent/WO2015196011A1/en
Publication of JP2017519768A publication Critical patent/JP2017519768A/ja
Publication of JP2017519768A5 publication Critical patent/JP2017519768A5/ja
Application granted granted Critical
Publication of JP6845016B2 publication Critical patent/JP6845016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016573926A 2014-06-19 2015-06-19 多細菌性感染の治療 Active JP6845016B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462014506P 2014-06-19 2014-06-19
US62/014,506 2014-06-19
US201562140849P 2015-03-31 2015-03-31
US62/140,849 2015-03-31
PCT/US2015/036576 WO2015196011A1 (en) 2014-06-19 2015-06-19 Treatment of polybacterials infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020209896A Division JP2021063090A (ja) 2014-06-19 2020-12-18 多細菌性感染の治療

Publications (3)

Publication Number Publication Date
JP2017519768A JP2017519768A (ja) 2017-07-20
JP2017519768A5 true JP2017519768A5 (https=) 2018-08-09
JP6845016B2 JP6845016B2 (ja) 2021-03-17

Family

ID=54936121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016573926A Active JP6845016B2 (ja) 2014-06-19 2015-06-19 多細菌性感染の治療
JP2020209896A Pending JP2021063090A (ja) 2014-06-19 2020-12-18 多細菌性感染の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020209896A Pending JP2021063090A (ja) 2014-06-19 2020-12-18 多細菌性感染の治療

Country Status (11)

Country Link
US (1) US11168132B2 (https=)
EP (1) EP3157565B1 (https=)
JP (2) JP6845016B2 (https=)
KR (1) KR102549870B1 (https=)
CN (1) CN106456767B (https=)
AU (1) AU2015276938B2 (https=)
CA (1) CA2952278A1 (https=)
ES (1) ES2983252T3 (https=)
SG (2) SG10201811361XA (https=)
TW (1) TWI719938B (https=)
WO (1) WO2015196011A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112014011028B1 (pt) 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
US9845348B2 (en) 2012-11-06 2017-12-19 Medimmune, Llc Methods of treating S. aureus-associated diseases
MX375324B (es) * 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
US11066461B2 (en) 2015-11-30 2021-07-20 Medimmune Limited Method for preventing or treating nosocomial pneumonia
EA201892525A1 (ru) 2016-05-05 2019-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Конструкции днк-антител для применения против pseudomonas aeruginosa
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
CN113811544A (zh) * 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
SG11202112462RA (en) * 2019-06-11 2021-12-30 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
FR3114970B1 (fr) * 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2025117765A1 (en) * 2023-12-01 2025-06-05 University Of Washington Protective monoclonal antibodies to pseudomonas aeruginosa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043690A1 (en) 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
CA2784033A1 (en) * 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
EP3470526A3 (en) 2011-02-08 2019-07-17 Medimmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
BR112014011028B1 (pt) * 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
JP2015535005A (ja) 2012-11-06 2015-12-07 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療
MX375324B (es) 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
US9845348B2 (en) 2012-11-06 2017-12-19 Medimmune, Llc Methods of treating S. aureus-associated diseases
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody

Similar Documents

Publication Publication Date Title
JP2017519768A5 (https=)
JP2021063090A5 (https=)
King Bronchiectasis
JP6845016B2 (ja) 多細菌性感染の治療
DiGiandomenico et al. Antibacterial monoclonal antibodies: the next generation?
Sulakvelidze et al. Bacteriophages as therapeutic agents
US10835607B2 (en) Monoclonal antibody and vaccine targeting filamentous bacteriophage
JP2016507470A5 (https=)
Munita et al. Enterococcal endocarditis: can we win the war?
JP2013515079A5 (https=)
HRP20201370T1 (hr) Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
Bezáková et al. Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants
RU2016116949A (ru) Анти-лпс о11-антитело
JP2018529661A5 (https=)
JP2015536951A5 (https=)
JP2018535227A (ja) 院内肺炎を予防または治療する方法
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
JP2012516897A5 (https=)
CN111372603A (zh) 针对铜绿假单胞菌感染的组合物和方法
JP2008526848A (ja) 黄色ブドウ球菌感染を治療する方法
Tur Clinical Microbiology and Infectious Diseases (ECCMID)-28th European Congress. Madrid, Spain-April 21-24, 2018
Kim et al. Infective endocarditis prophylaxis before dental procedures: New guidelines spark controversy
Projan Antibodies for the Prevention, Treatment, and Preemption of Infectious Diseases
Tümmler aeruginosa [version 1; peer review: 2 approved]
AI Valasidis et al. Novel antimicrobial agents for the management of maxillofacial and neck infections